News and Links
Join us at the Keystone meeting on PI3K Pathways in Immunology, Growth Disorders and Cancer:
We are part of PI3K biology in health and disease (Phd), an EU-funded training network for PhD students.
See more details at http://pi3k-phdproject.eu/
Two clinical trials of PI3Kδ inhibitors for treatment of APDS announced on Clinicaltrials.gov:
The Immune Army is here!
Free book of reviews on PI3K in the immune system:
available to download from Frontiers in Immunology
(edited by Klaus Okkenhaug, Martin Turner and Michael Gold).
A brief history of PI3K research at the Babraham Institute and its impact, published by the BBSRC:
Idelalisib (Zydelig) is the first PI3K inhibitor to receive FDA approval.
Idelalisib is a PI3K p110δ isoform selective inhibitor which has been approved in the US for the treatment of three different types of B cell cancers (lymphoma).
Inactivation of the PI3K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
See our article in Nature
The press has picked up on this story:
The Telegraph (front page!): Cancer pill fights disease and gives lifelong protection.
The Daily Mail: Leukaemia pill could help fight other types of cancer: Drug may also stop disease returning by restricting tumour growth
The Scotsman: Leukaemia drug could beat range of cancers
Some journals have published commentaries on this article:
Cancer Discovery: PI3Kδ Regulates Immune Tolerance to Cancer
Cell: Waging War on Cancer with the Sword of Immunity
Nature (News and Views by Hirsch and Novelli): Cancer: Natural-born killers unleashed
Nature Reviews Clinical Oncology: PI3Kδ inhibition lifts the breaks on antitumour immunity
Nature Reviews Drug Discovery: Horizons broaden for PI3Kδ inhibitors
PI3Kδ inhibitors showing remarkable results in leukaemia
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia R.R. Furman and Others http://www.nejm.org/doi/full/10.1056/NEJMoa1315226
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma A.K. Gopal and Others http://www.nejm.org/doi/full/10.1056/NEJMoa1314583
See also our commentary at: Nature Reviews Clinical Oncology
Activating mutations in p110δ causes susceptibility to recurrent infections
See article in Science.
Ed Banham-Hall has made a web site with information about Activated PI3K delta syndrome (APDS) with information for patients, doctors and scientists.
Immunology in Cambridge
(Research directory, seminar list and more).